Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
This study is conducted in Europe and Asia. The aim of this observational study is to monitor
 antibody formation towards the room temperature stable formulation of NovoSeven® (activated
 recombinant human factor VII).
Inclusion Criteria:

 -  Diagnosed with congenital haemophilia A or B with inhibitors to factor VIII or factor
 IX

 -  Treated with room temperature stable NovoSeven®